ReShape Lifesciences Inc. (RSLS) Misses Q3 EPS by 77c

ReShape Lifesciences Inc. (NASDAQ: RSLS) reported Q3 EPS of ($1.06), $0.77 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $360 thousand versus the consensus estimate of $310 thousand.

For earnings history and earnings-related data on ReShape Lifesciences Inc. (RSLS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M